Document and Entity Information
Document and Entity Information - USD ($) | 5 Months Ended | |
Dec. 31, 2020 | Mar. 31, 2021 | |
Document Information [Line Items] | ||
Document Type | 10-K/A | |
Document Period End Date | Dec. 31, 2020 | |
Entity Registrant Name | Horizon Acquisition Corp II | |
Transition Report | false | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Shell Company | true | |
Entity Central Index Key | 0001821788 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | FY | |
Amendment Flag | true | |
Entity Well-known Seasoned Issuer | No | |
Entity Voluntary Filers | No | |
Entity Public Float | $ 542,325,000 | |
Document Annual Report | true | |
Amendment Description | Amendment No. 1 | |
Class A ordinary shares | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Class A ordinary shares included as part of the units | |
Trading Symbol | HZON | |
Security Exchange Name | NYSE | |
Entity Common Stock, Shares Outstanding | 52,500,000 | |
Redeemable warrants, each warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 | |
Trading Symbol | HZON.WS | |
Security Exchange Name | NYSE | |
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-third of one redeemable warrant | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-third of one redeemable warrant | |
Trading Symbol | HZON.U | |
Security Exchange Name | NYSE | |
Class B ordinary shares | ||
Document Information [Line Items] | ||
Entity Common Stock, Shares Outstanding | 13,125,000 |
BALANCE SHEET
BALANCE SHEET | Dec. 31, 2020USD ($) |
Current assets: | |
Cash | $ 823,192 |
Prepaid expenses | 510,017 |
Total current assets | 1,333,209 |
Investments held in Trust Account | 525,003,145 |
Total Assets | 526,336,354 |
Current liabilities: | |
Accounts payable | 6,000 |
Accrued expenses | 208,037 |
Total current liabilities | 214,037 |
Deferred underwriting commissions | 12,950,000 |
Derivative warrant liabilities | 45,156,670 |
Total liabilities | 58,320,707 |
Commitments and Contingencies (Note 6) | |
Class A ordinary shares; 46,301,564 shares subject to possible redemption at $10.00 per share | 463,015,640 |
Shareholders' Equity: | |
Preference shares, $0.0001 par value 1,000,000 shares authorized none issued and outstanding | |
Additional paid-in capital | 15,581,675 |
Accumulated deficit | (10,583,601) |
Total shareholders' equity | 5,000,007 |
Total Liabilities and Shareholders' Equity | 526,336,354 |
Class A ordinary shares | |
Shareholders' Equity: | |
Ordinary shares | 620 |
Class B ordinary shares | |
Shareholders' Equity: | |
Ordinary shares | $ 1,313 |
BALANCE SHEET (Parenthetical)
BALANCE SHEET (Parenthetical) | Dec. 31, 2020$ / sharesshares |
Preference shares, par value | $ / shares | $ 0.0001 |
Preference shares, shares authorized | 1,000,000 |
Preference shares, shares issued | 0 |
Preference shares, shares outstanding | 0 |
Class A ordinary shares | |
Ordinary shares, par value | $ / shares | $ 0.0001 |
Ordinary shares, authorized shares | 400,000,000 |
Ordinary shares, shares issued | 6,198,436 |
Ordinary shares, shares outstanding | 6,198,436 |
Number of shares subject to possible redemption | 46,301,564 |
Shares subject to possible redemption, par value per share | $ / shares | $ 10 |
Class B ordinary shares | |
Ordinary shares, par value | $ / shares | $ 0.0001 |
Ordinary shares, authorized shares | 40,000,000 |
Ordinary shares, shares issued | 13,125,000 |
Ordinary shares, shares outstanding | 13,125,000 |
STATEMENT OF OPERATIONS
STATEMENT OF OPERATIONS | 5 Months Ended |
Dec. 31, 2020USD ($)$ / sharesshares | |
General and administrative expenses | $ 249,892 |
Loss from operations | (249,892) |
Change in fair value of derivative liabilities | (9,269,010) |
Financing Costs | (1,067,843) |
Interest income from investments held in Trust Account | 3,144 |
Net loss | $ (10,583,601) |
Class A redeemable ordinary shares | |
Basic and diluted weighted average shares outstanding | shares | 51,232,394 |
Basic and diluted net income per share | $ / shares | $ 0 |
Class B non-redeemable ordinary shares | |
Basic and diluted weighted average shares outstanding | shares | 12,648,810 |
Basic and diluted net income per share | $ / shares | $ (0.84) |
STATEMENT OF CHANGES IN SHAREHO
STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 5 months ended Dec. 31, 2020 - USD ($) | Class A ordinary sharesOrdinary shares | Class B ordinary sharesOrdinary shares | Additional Paid-in Capital | Accumulated Deficit | Total |
Balance at the beginning at Jul. 21, 2020 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Balance at the beginning (in shares) at Jul. 21, 2020 | 0 | 0 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Issuance of Class B ordinary shares to Sponsor | $ 1,438 | 23,562 | 25,000 | ||
Issuance of Class B ordinary shares to Sponsor (in shares) | 14,375,000 | ||||
Sale of units in initial public offering, gross | $ 5,250 | 498,569,750 | 498,575,000 | ||
Sale of units in initial public offering, gross (in shares) | 52,500,000 | ||||
Offering costs | (19,938,092) | (19,938,092) | |||
Excess of cash received over fair value of private placement warrants | (62,660) | (62,660) | |||
Forfeiture of Class B ordinary shares | $ (125) | 125 | |||
Forfeiture of Class B ordinary shares (in shares) | (1,250,000) | ||||
Class A Shares subject to possible redemption | $ (4,630) | (463,011,010) | (463,015,640) | ||
Class A Shares subject to possible redemption (in shares) | (46,301,564) | ||||
Net loss | (10,583,601) | (10,583,601) | |||
Balance at the end at Dec. 31, 2020 | $ 620 | $ 1,313 | $ 15,581,675 | $ (10,583,601) | $ 5,000,007 |
Balance at the end (in shares) at Dec. 31, 2020 | 6,198,436 | 13,125,000 |
STATEMENT OF CASH FLOWS
STATEMENT OF CASH FLOWS | 5 Months Ended |
Dec. 31, 2020USD ($) | |
Cash Flows from Operating Activities: | |
Net loss | $ (10,583,601) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Financing cost - derivative warrant liabilities | 1,067,843 |
Change in fair value of derivative warrant liabilities | 9,269,010 |
Interest income from investments held in Trust Account | (3,144) |
Changes in operating assets and liabilities: | |
Prepaid expenses | (485,017) |
Accounts payable | (392,251) |
Accrued expenses | 123,037 |
Net cash used in operating activities | (1,004,123) |
Cash Flows from Investing Activities: | |
Cash deposited in Trust Account | (525,000,000) |
Net cash used in investing activities | (525,000,000) |
Cash Flows from Financing Activities: | |
Repayment of note payable to related party | (161,385) |
Proceeds received from initial public offering, gross | 525,000,000 |
Proceeds received from private placement | 9,400,000 |
Offering costs paid | (7,411,300) |
Net cash provided by financing activities | 526,827,315 |
Net increase in cash | 823,192 |
Cash - beginning of the period | 0 |
Cash - ending of the period | 823,192 |
Supplemental disclosure of noncash investing and financing activities: | |
Prepaid expenses paid by Sponsor in exchange for issuance of Class B ordinary shares | 25,000 |
Offering costs included in accounts payable | 398,250 |
Offering costs included in accrued expenses | 85,000 |
Offering costs paid through note payable to Sponsor | 161,385 |
Deferred underwriting commissions | 12,950,000 |
Initial value of Class A ordinary shares subject to possible redemption | 473,752,900 |
Change in value of Class A ordinary shares subject to possible redemption | (10,737,260) |
Initial fair value of warrant liabilities | $ 35,887,660 |
DESCRIPTION OF ORGANIZATION, BU
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | 5 Months Ended |
Dec. 31, 2020 | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | |
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION | NOTE 1. Organization and General Horizon Acquisition Corporation II (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on July 22, 2020. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses that the Company has not yet identified (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to focus on the media and entertainment industries. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”). As of December 31, 2020, the Company had not yet commenced operations. All activity for the period from July 22, 2020 (inception) through December 31, 2020 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”), which is described below, and since offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenue until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of income earned on investments in the Trust Account. The Company has selected December 31 as its fiscal year end. Sponsor and Initial Public Offering The Company’s sponsor is Horizon II Sponsor, LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Initial Public Offering was declared effective on October 19, 2020. On October 22, 2020, the Company consummated the Initial Public Offering of 50,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $500.0 million, and incurring offering costs of approximately $19.6 million, inclusive of approximately $12.1 million in deferred underwriting commissions (Note 7). The underwriter was granted a 45‑day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 5,175,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The Underwriters exercised the over-allotment option on November 24, 2020 to purchase an additional 2,500,000 Units (the “Over-Allotment Units”), which closed on November 27, 2020 generating gross proceeds of $25.0 million (the “Over-Allottment”), and incurring additional offering costs of approximately $1.4 million in underwriting fees (inclusive of approximately $0.9 million in deferred underwriting fees). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 5,933,333 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) to the Sponsor, each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.50 per Private Placement Warrant, generating gross proceeds to the Company of approximately $8.9 million (Note 5), pursuant to the Private Placement Warrants Purchase Agreement, dated October 19, 2020 (the “Private Placement Purchase Agreement”), by and between the Company and the Sponsor. The Private Placement Purchase Agreement provided for a second closing (the “Second Closing”) of the Private Placement simultaneously with the closing of the Over-Allotment Units. Accordingly, on November 27, 2020, the Second Closing of the Private Placement was consummated, resulting in the purchase of an aggregate of 333,334 Private Placement Warrants by the Sponsor, generating gross proceeds of $0.5 million. The Sponsor agreed to forfeit up to 1,875,000 Class B ordinary shares, par value $0.0001 (the “founder shares”) to the extent that the over-allotment option is not exercised in full by the underwriters, so that the founder shares will represent 20% of the Company’s issued and outstanding shares after the IPO. On October 22, 2020, in connection with consummation of the Sponsor IPO Units, the Sponsor surrendered 581,250 founder shares to the Company for no consideration, thus reducing the amount of Class B ordinary shares subject to forfeiture to 1,293,750 Class B ordinary shares. As a result of the underwriters’ partial exercise of the over-allotment option, and the remainder of the over-allotment units expiring unexercised, on December 3, 2020, an additional 668,750 Class B ordinary shares were automatically surrendered for no consideration by the Sponsor. Trust Account Upon the closing of the Initial Public Offering, the Over-Allotment, and the Private Placements, a total of $525.0 million ($10.00 per Unit) of the net proceeds of the Initial Public Offering and Over-Allotment, and certain of the proceeds of the Private Placement was placed in a trust account (“Trust Account”) with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a‑7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. Initial Business Combination The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target business or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended, or the Investment Company Act. The Company will provide its holders of the Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The public shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to public shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). These Public Shares were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to the amended and restated memorandum and articles of association which will be adopted by the Company upon the consummation of the Initial Public Offering (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each public shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the founder shares prior to this Initial Public Offering (the “Initial Shareholders”) have agreed to vote their Founder Shares (as defined in Note 6) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their founder shares and Public Shares in connection with the completion of a Business Combination. In addition, the Company has agreed not to enter into a definitive agreement regarding an initial Business Combination without the prior consent of the Sponsor. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association will provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, officers, directors and director nominees have agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association (A) to modify the substance or timing of the Company’s obligation to allow the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, October 22, 2022 (the “Combination Period”), or (B) with respect to any other provisions relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the public shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. In connection with the redemption of 100% of the Company’s outstanding Public Shares for a portion of the funds held in the Trust Account, each holder will receive a full pro rata portion of the amount then in the Trust Account, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay the Company’s taxes payable (less taxes payable and up to $100,000 of interest to pay dissolution expenses). The Initial Shareholders have agreed to waive their liquidation rights with respect to the founder shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 7) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution in the Trust Account will be less than the $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the Trust Account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. There can be no guarantee that the Company will be successful in obtaining such waivers from its targeted vendors and service providers. Basis of presentation The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. As described in Note 2—Restatement of Previously Issued Financial Statements, the Company’s financial statements as of October 22, 2020, as of and for the period from July 22, 2020 (inception) through December 31, 2020 (collectively, the “Affected Periods”), are restated in this Annual Report on Form 10-K/A (Amendment No. 1) (this “Annual Report”) to correct the misapplication of accounting guidance related to the Company’s warrants in the Company’s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as “Restated” in the audited and unaudited condensed financial statements and accompanying notes, as applicable. See Note 2—Restatement of Previously Issued Financial Statements for further discussion. Emerging growth company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Liquidity and Capital Resources As of December 31, 2020, the Company had approximately $823,000 in cash outside of the Trust Account and working capital of approximately $1.1 million. The Company’s liquidity needs up to December 31, 2020 have been satisfied through the payment of $25,000 from the Sponsor to cover certain expenses in exchange for the issuance of the founder shares (as defined in Note 6), a loan of approximately $161,000 pursuant to the Note issued to the Sponsor (Note 6). The Company repaid the Note in full on October 22, 2020. Subsequent to the consummation of the Initial Public Offering and Private Placement, the Company’s liquidity needs have been satisfied with the proceeds from the consummation of the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor may, but is not obligated to, provide the Company working capital loans (see Note 6). As of December 31, 2020, there were no amounts outstanding under any Working Capital Loan. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. |
RESTATEMENT OF PREVIOUSLY ISSUE
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS | 5 Months Ended |
Dec. 31, 2020 | |
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS | |
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS | NOTE 2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance in October 2020, the Company’s warrants were accounted for as equity within the Company’s previously reported balance sheets. After discussion and evaluation, including with the Company’s independent registered public accounting firm and the Company’s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement. Historically, the warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the warrants, based on our application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for warrants issued in October and November of 2020, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company’s Statement of Operations each reporting period. Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued Financial Statements for the Affected Periods should be restated because of a misapplication in the guidance around accounting for certain of our outstanding Warrants to purchase ordinary shares and should no longer be relied upon. Impact of the Restatement The impact of the restatement on the audited consolidated balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities. As of December 31, 2020 As Previously Restatement Reported Adjustment As Restated Balance Sheet Total assets $ 526,336,354 $ — $ 526,336,354 Liabilities and shareholders’ equity Total current liabilities $ 214,037 $ — $ 214,037 Deferred underwriting commissions 12,950,000 — 12,950,000 Derivative warrant liabilities — 45,156,670 45,156,670 Total liabilities 13,164,037 45,156,670 58,320,707 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders’ equity 508,172,310 (45,156,670) 463,015,640 Preference shares - $0.0001 par value — — — Class A ordinary shares - $0.0001 par value 168 452 620 Class B ordinary shares - $0.0001 par value 1,313 — 1,313 Additional paid-in-capital 5,245,274 10,336,401 15,581,675 Accumulated deficit (246,748) (10,336,853) (10,583,601) Total shareholders’ equity 5,000,007 — 5,000,007 Total liabilities and shareholders’ equity $ 526,336,354 $ — $ 526,336,354 Period From July 22, 2020 (Inception) Through December 31, 2020 As Previously Restatement Reported Adjustment As Restated Statement of Operations Loss from operations $ (249,892) $ — $ (249,892) Other (expense) income: Change in fair value of derivative warrant liabilities — (9,269,010) (9,269,010) Financing cost -derivative warrant liabilities — (1,067,843) (1,067,843) Interest income from investments held in Trust Account 3,144 — 3,144 Total other (expense) income 3,144 (10,336,853) (10,333,709) Net loss $ (246,748) $ (10,336,853) $ (10,583,601) Basic and Diluted weighted-average Class A ordinary shares outstanding 51,232,394 51,232,394 Basic and Diluted net loss per Class A share $ 0.00 $ 0.00 Basic and Diluted weighted-average Class B ordinary shares outstanding 12,648,810 12,648,810 Basic and Diluted net loss per Class B share $ (0.02) $ (0.82) $ (0.84) Period From July 22, 2020 (Inception) Through December 31, 2020 As Previously Restatement Reported Adjustment As Restated Statement of Cash Flows Net cash used in operating activities (1,004,123) — (1,004,123) Net cash used in investing activities (525,000,000) — (525,000,000) Net cash provided by financing activities 526,827,315 — 526,827,315 Net change in cash $ 823,192 $ — $ 823,192 In addition, the impact to the balance sheet dated October 22, 2020, filed on Form 8-K on October 28, 2020 is presented below. As of October 22, 2020 As Previously Restatement Reported Adjustment As Restated Balance Sheet Total assets $ 502,377,315 $ — $ 502,377,315 Liabilities and shareholders’ equity Total current liabilities $ 1,036,746 $ — $ 1,036,746 Deferred underwriting commissions 12,075,000 — 12,075,000 Derivative warrant liabilities — 34,126,000 34,126,000 Total liabilities 13,111,746 34,126,000 47,237,746 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders’ equity 484,265,560 (34,126,000) 450,139,560 Preference shares - $0.0001 par value — — — Class A ordinary shares - $0.0001 par value 157 342 499 Class B ordinary shares - $0.0001 par value 1,380 — 1,380 Additional paid-in-capital 5,026,968 1,067,501 6,094,469 Accumulated deficit (28,496) (1,067,843) (1,096,339) Total shareholders’ equity 5,000,009 — 5,000,009 Total liabilities and shareholders’ equity $ 502,377,315 $ — $ 502,377,315 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 5 Months Ended |
Dec. 31, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at December 31, 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000, and any investments held in Trust Account. At December 31, 2020, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. The Company’s investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in a money market funds that comprise only U.S. Treasury securities, or a combination thereof. Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020, the carrying values of cash, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s investments held in Trust Account are comprised of investments in U.S. government securities with an original maturity of 185 days or less or investments in a money market funds that invest in only U.S. government securities and are recognized at fair value. The fair value of investments held in Trust Account is determined using quoted prices in active markets. The fair value of warrants issued in connection with the Initial Public Offering, exercise of the over-allotment option and Private Placement were initially and subsequently measured at fair value using a Monte Carlo simulation model. Beginning as of December 31, 2020, the fair value of Public Warrants have been measured based on the listed market price of such Public Warrants. The Private Placement Warrants continue to be measured at fair value using a Monte Carlo simulation model through December 31, 2020. Offering Costs Associated with Initial Public Offering Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred and presented as non-operating expenses in the statement of operations. Offering costs associated with the Public Shares were charged to shareholders’ equity. Of the total offering costs of the Initial Public Offering, approximately $1.1 million is included in financing cost - derivative warrant liabilities in the statement of operations and $19.9 million is included in shareholders’ equity. Class A Ordinary Shares Subject to Possible Redemption Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2020, 46,301,564 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the balance sheet. Derivative Warrant liabilities The Company did not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments, including issued warrants to purchase Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued an aggregate of 17,500,000 warrants on Class A ordinary shares in the Initial Public Offering and upon the underwriters’ exercise of a portion of their over-allotment option and issued 6,266,667 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognized the warrant instruments as liabilities at fair value and adjusted the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued in connection with the Initial Public Offering, exercise of the over-allotment option and Private Placement were initially and subsequently measured at fair value using a Monte Carlo simulation model. As of December 31, 2020, the fair value of Public Warrants have been measured based on the listed market price of such Public Warrants. The Private Placement Warrants continue to be measured at fair value using a Monte Carlo simulation model through December 31, 2020. Net Income (Loss) per Ordinary Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares that remain subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase an aggregate of 23,766,667 shares of Class A ordinary shares in the calculation of diluted earnings per share, since their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The Company’s statement of operations includes a presentation of income per share for Class A ordinary shares subject to redemption in a manner similar to the two-class method of income per share. Net income per share, basic and diluted, for Class A ordinary shares is calculated by dividing the investment income earned on the Trust Account of approximately $3,000 for the period from July 22, 2020 (inception) through December 31, by the weighted average number of shares of Class A ordinary shares outstanding for the period. Net loss per share, basic and diluted, for Class B ordinary shares is calculated by dividing the net loss of approximately $10.6 million for the period from July 22, 2020 (inception) through December 31, 2020, less income attributable to Class A ordinary shares, by the weighted average number of shares of Class B ordinary shares outstanding for the period. Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. |
INITIAL PUBLIC OFFERING
INITIAL PUBLIC OFFERING | 5 Months Ended |
Dec. 31, 2020 | |
INITIAL PUBLIC OFFERING | |
INITIAL PUBLIC OFFERING | NOTE 4. INITIAL PUBLIC OFFERING On October 22, 2020, the Company consummated the Initial Public Offering of 50,000,000 Units, at $10.00 per Unit, generating gross proceeds of $500.0 million, and incurring offering costs of approximately $19.6 million, inclusive of approximately $12.1 million in deferred underwriting commissions. The Sponsor had purchased 15,500,000 Units ( the “Sponsor IPO Units”) at the Initial Public Offering price. The underwriters did not receive any underwriting discounts or commissions on the Sponsor IPO Units . The underwriter is granted a 45‑day option from the date of the final prospectus relating to the Initial Public Offering to purchase up to 5,175,000 additional Units to cover over-allotments, if any, at $10.00 per Unit. The Underwriters exercised the over-allotment option on November 24, 2020 to purchase an additional 2,500,000 Units (the “Over-Allotment Units”), which closed on November 27, 2020 generating gross proceeds of $25.0 million, and incurring additional offering costs of approximately $1.4 million in underwriting fees (inclusive of approximately $0.9 million in deferred underwriting fees). Each Unit will consist of one Class A ordinary share and one-third of one redeemable warrant (“Public Warrant”). Each whole Public Warrant will entitle the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustment (see Note 8). |
PRIVATE PLACEMENT
PRIVATE PLACEMENT | 5 Months Ended |
Dec. 31, 2020 | |
PRIVATE PLACEMENT | |
PRIVATE PLACEMENT | NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 5,933,333 Private Placement Warrants to the Sponsor, each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.50 per Private Placement Warrant, generating gross proceeds to the Company of approximately $8.9 million. On November 27, 2020, the Second Closing of the Private Placement was consummated, resulting in the purchase of an aggregate of 333,334 Private Placement Warrants by the Sponsor, generating gross proceeds of $0.5 million. Each whole Private Placement Warrant is exercisable for one whole Class A ordinary share at a price of $11.50 per share. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable except as described below in Note 8 and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. The Sponsor and the Company’s officers and directors will agree, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 5 Months Ended |
Dec. 31, 2020 | |
RELATED PARTY TRANSACTIONS | |
RELATED PARTY TRANSACTIONS | NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares On August 7, 2020, the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 Class B ordinary shares (the “founder shares”). The Sponsor agreed to forfeit up to 1,875,000 Class B ordinary shares, par value $0.0001 (the “founder shares”) to the extent that the over-allotment option is not exercised in full by the underwriters, so that the Founder Shares will represent 20% of the Company’s issued and outstanding shares after the IPO. On October 22, 2020, in connection with consummation of the Sponsor IPO Units, the Sponsor surrendered 581,250 founder shares to the Company for no consideration, thus reducing the amount of Class B ordinary shares subject to forfeiture to 1,293,750 Class B ordinary shares. As a result of the underwriters’ partial exercise of the over-allotment option, and the remainder of the over-allotment units expiring unexercised, on December 3, 2020, 668,750 Class B ordinary shares were automatically surrendered for no consideration by the Sponsor. The Initial Shareholders agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or earlier if, subsequent to the initial Business Combination, the closing price of the Class A ordinary share equals or exceeds $12.00 per share (as adjusted for share sub-divisions, capitalization of shares, share dividends, rights issuances, subdivisions reorganizations, recapitalizations and the like) for any 20 trading days within any 30‑trading day period commencing at least 150 days after the initial Business Combination, and (B) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property. Related Party Loans On August 7, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note is non-interest bearing, unsecured and due upon the closing of the Initial Public Offering. The Company borrowed approximately $161,000 under the Note and fully repaid the Note on October 22, 2020. In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“working capital loans”). If the Company completes a Business Combination, the Company may repay the working capital loans out of the proceeds of the Trust Account released to the Company. Otherwise, the working capital loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the working capital loans but no proceeds held in the Trust Account would be used to repay the working capital loans. The working capital loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such working capital loans may be convertible into warrants of the post Business Combination entity at a price of $1.50 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such working capital loans, if any, have not been determined and no written agreements exist with respect to such loans. As of December 31, 2020, the Company had no borrowings under the working capital loans. Administrative Support Agreement The Company agreed to pay the Sponsor a total of $10,000 per month, commencing on the date of listing on the NYSE, for office space, utilities, secretarial and administrative support services provided to members of the management team. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. From the date the securities were first listed on the NYSE through December 31, 2020, the Sponsor waived the fee. In addition, the Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on the Company’s behalf such as identifying potential target businesses and performing due diligence on suitable Business Combinations. The Audit Committee of the Board of Directors will review on a quarterly basis all payments that are made by the Company to the Sponsor, officers or directors, or their affiliates. Any such payments prior to an initial Business Combination will be made from funds held outside the Trust Account. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 5 Months Ended |
Dec. 31, 2020 | |
COMMITMENTS AND CONTINGENCIES | |
COMMITMENTS AND CONTINGENCIES | NOTE 7. COMMITMENTS AND CONTINGENCIES Registration and Shareholder Rights The holders of the founder shares, Private Placement Warrants and warrants that may be issued upon conversion of working capital loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of working capital loans) are entitled to registration rights pursuant to a registration and shareholder rights. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45‑day option from October 16, 2020, the date of the final prospectus, to purchase up to 5,175,000 additional Units at the Initial Public Offering price less the underwriting discounts and commissions. On November 27, 2020, the Company issued an additional of 2,500,000 Units at the Initial Public Offering price at $10.00 per Unit pursuant to the partial exercise of the underwriters’ over-allotment option. The underwriters were entitled to an underwriting discount of $0.20 per unit (excluding the Sponsor IPO Units), or $7.4 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit (excluding the Affiliated Units), or $12.95 million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In connection with the consummation of the sale of Units pursuant to the over-allotment option on November 27, 2020, the underwriters were entitled to an additional fee of approximately $1.4 million paid upon closing and an additional deferred underwriting commissions of approximately $0.9 million. Risks and Uncertainties Management continues to evaluate the impact of the COVID‑19 pandemic and has concluded that, while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. |
DERIVATIVE WARRANT LIABILITIES
DERIVATIVE WARRANT LIABILITIES | 5 Months Ended |
Dec. 31, 2020 | |
DERIVATIVE WARRANT LIABILITIES | |
DERIVATIVE WARRANT LIABILITIES | NOTE 8. As of December 31, 2020, the Company had 17,500,000 and 6,266,667 Public Warrants and Private Placement Warrants, respectively, outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of an initial Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permit holders to exercise their warrants on a cashless basis under certain circumstances). The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use commercially reasonable efforts to file with the SEC a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and to maintain a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60 th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of the initial Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any founder shares held by the Initial Shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of Class A ordinary shares during the 10‑trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price See “— Redemption of warrants when the price per class A ordinary share equals or exceeds $18.00” and “— Redemption of warrants when the price per class A ordinary share equals or exceeds $10.00” as described below. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except (i) that the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (ii) except as described below, the Private Placement Warrants will be non-redeemable so long as they are held by the Sponsor or such its permitted transferees and (iii) the Sponsor or its permitted transferees will have the option to exercise the Private Placement Warrants on a cashless basis and have certain registration rights. If the Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by such holders on the same basis as the Public Warrants. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants): · in whole and not in part; · at a price of $0.01 per warrant; · upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and · if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30‑trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may call the outstanding warrants for redemption (except as described herein with respect to the Private Placement Warrants): · in whole and not in part; · at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of Class A ordinary shares to be determined by reference to an agreed table based on the redemption date and the “fair market value” of Class A ordinary shares; · if, and only if, the closing price of Class A ordinary shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30‑trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and · if the closing price of the Class A ordinary shares for any 20 trading days within a 30‑trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. The “fair market value” of Class A ordinary shares for the above purpose shall mean the volume weighted average price of Class A ordinary shares during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 Class A ordinary shares per warrant (subject to adjustment). In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. |
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY | 5 Months Ended |
Dec. 31, 2020 | |
SHAREHOLDERS' EQUITY | |
SHAREHOLDERS' EQUITY | NOTE 9. SHAREHOLDERS’ EQUITY Class A Ordinary Shares — The Company is authorized to issue 400,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of the Company’s Class A ordinary shares are entitled to one vote for each share. At December 31, 2020, there were 52,500,000 Class A ordinary shares issued or outstanding, including 46,301,564 Class A ordinary shares subject to possible redemption. Class B Ordinary Shares — The Company is authorized to issue 40,000,000 Class B ordinary shares with a par value of $0.0001 per share. On August 7, 2020, 14,375,000 Class B ordinary shares were issued and outstanding including an aggregate of up to 1,875,000 Class B ordinary shares that are subject to forfeiture, to the Company by the Initial Shareholders for no consideration to the extent that the underwriters’ over-allotment option is not exercised in full or in part, so that the Class B ordinary shares will collectively represent 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering. On October 22, 2020, in connection with consummation of the Sponsor IPO Units, the Sponsor surrendered 581,250 founder shares to the Company for no consideration, thus reducing the amount of Class B ordinary shares subject to forfeiture to 1,293,750 Class B ordinary shares. As a result of the underwriters’ partial exercise of the over-allotment option, which closed on November 27, 2020, and the remaining over-allotment units expiring unexercised, 668,750 Class B ordinary shares were surrendered by the Sponsor on December 3, 2020. Accordingly, as of December 31, 2020, there were 13,125,000 Class B ordinary shares outstanding, with no shares were subject to forfeiture. Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders and holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law; provided that only holders of Class B ordinary shares will have the right to vote on the appointment of directors prior to or in connection with the completion of the initial Business Combination. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the consummation of the initial Business Combination on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with the initial Business Combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, 20% of the total number of Class A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class A ordinary shares by Public Shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one basis. Preference Shares — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share . As of December 31, 2020, there were no preference shares issued or outstanding. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 5 Months Ended |
Dec. 31, 2020 | |
FAIR VALUE MEASUREMENTS | |
FAIR VALUE MEASUREMENTS | NOTE 10. FAIR VALUE MEASUREMENTS The following table presents information about the Company’s financial assets and financial liabilities that are measured at fair value on a recurring basis as of December 31, 2020 by level within the fair value hierarchy: Quoted Significant Significant Prices Other Other in Active Observable Unobservable Markets Inputs Inputs Description (Level 1) (Level 2) (Level 3) Assets Investments held in Trust Account $ 525,003,145 $ — $ — Liabilities Derivative warrant liabilities -Public Warrants $ 33,250,000 $ — $ — Derivative warrant liabilities -Private Warrants $ — $ — $ 11,906,670 Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in December 2020, when the Public Warrants were separately listed and traded. Level 1 instruments include investments in government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model. The fair value of Public Warrants issued in connection with the Initial Public Offering have been measured based on the listed market price of such warrants, a Level 1 measurement, since December 2020. The Private Placement Warrants continue to be measured at fair value using a Monte Carlo simulation model through December 31, 2020. For the period ended December 31, 2020, the Company recognized a charge to the statement of operations resulting from an increase in the fair value of liabilities of approximately $9.3 million presented as change in fair value of derivative warrant liabilities on the accompanying statement of operations. The estimated fair value of the Public Warrants prior to being separately listed and traded, and the Private Placement Warrants were determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares warrants based on implied volatility from the Company’s traded warrants and from historical volatility of select peer company’s ordinary shares that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 fair value measurements inputs at the initial measurement date and at December 31, 2020: As of October 22, 2020 As of December 31, 2020 Volatility 24.0 % 25.8 % Share price $ 9.55 10.33 Risk-free rate 0.68 % 0.36 % Dividend yield 0.0 % 0.0 % The change in the fair value of the derivative warrant liabilities for the period from July 22, 2020 (inception) through December 31, 2020 is summarized as follows: Warrant liabilities at July 22, 2020 (inception) $ — Issuance of Public and Private Warrants 35,887,660 Change in fair value of warrant liabilities 9,269,010 Warrant liabilities at December 31, 2020 $ 45,156,670 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 5 Months Ended |
Dec. 31, 2020 | |
SUBSEQUENT EVENTS | |
SUBSEQUENT EVENTS | NOTE 11. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements which have not previously been disclosed within the financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 5 Months Ended |
Dec. 31, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Use of Estimates | Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents at December 31, 2020. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000, and any investments held in Trust Account. At December 31, 2020, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. The Company’s investments held in the Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less or investments in a money market funds that comprise only U.S. Treasury securities, or a combination thereof. |
Investments Held in the Trust Account | Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. As of December 31, 2020, the carrying values of cash, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to the short-term nature of the instruments. The Company’s investments held in Trust Account are comprised of investments in U.S. government securities with an original maturity of 185 days or less or investments in a money market funds that invest in only U.S. government securities and are recognized at fair value. The fair value of investments held in Trust Account is determined using quoted prices in active markets. The fair value of warrants issued in connection with the Initial Public Offering, exercise of the over-allotment option and Private Placement were initially and subsequently measured at fair value using a Monte Carlo simulation model. Beginning as of December 31, 2020, the fair value of Public Warrants have been measured based on the listed market price of such Public Warrants. The Private Placement Warrants continue to be measured at fair value using a Monte Carlo simulation model through December 31, 2020. |
Offering Costs Associated with Initial Public Offering | Offering Costs Associated with Initial Public Offering Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred and presented as non-operating expenses in the statement of operations. Offering costs associated with the Public Shares were charged to shareholders’ equity. Of the total offering costs of the Initial Public Offering, approximately $1.1 million is included in financing cost - derivative warrant liabilities in the statement of operations and $19.9 million is included in shareholders’ equity. |
Class A Ordinary Shares subject to possible redemption | Class A Ordinary Shares Subject to Possible Redemption Class A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2020, 46,301,564 shares of Class A ordinary shares subject to possible redemption are presented as temporary equity, outside of the shareholders’ equity section of the balance sheet. |
Derivative Warrant liabilities | Derivative Warrant liabilities The Company did not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Management evaluates all of its financial instruments, including issued warrants to purchase Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company issued an aggregate of 17,500,000 warrants on Class A ordinary shares in the Initial Public Offering and upon the underwriters’ exercise of a portion of their over-allotment option and issued 6,266,667 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognized the warrant instruments as liabilities at fair value and adjusted the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statement of operations. The fair value of warrants issued in connection with the Initial Public Offering, exercise of the over-allotment option and Private Placement were initially and subsequently measured at fair value using a Monte Carlo simulation model. As of December 31, 2020, the fair value of Public Warrants have been measured based on the listed market price of such Public Warrants. The Private Placement Warrants continue to be measured at fair value using a Monte Carlo simulation model through December 31, 2020. |
Net Income (Loss) per Ordinary Share | Net Income (Loss) per Ordinary Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares that remain subject to forfeiture. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase an aggregate of 23,766,667 shares of Class A ordinary shares in the calculation of diluted earnings per share, since their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted loss per share is the same as basic loss per share for the periods presented. The Company’s statement of operations includes a presentation of income per share for Class A ordinary shares subject to redemption in a manner similar to the two-class method of income per share. Net income per share, basic and diluted, for Class A ordinary shares is calculated by dividing the investment income earned on the Trust Account of approximately $3,000 for the period from July 22, 2020 (inception) through December 31, by the weighted average number of shares of Class A ordinary shares outstanding for the period. Net loss per share, basic and diluted, for Class B ordinary shares is calculated by dividing the net loss of approximately $10.6 million for the period from July 22, 2020 (inception) through December 31, 2020, less income attributable to Class A ordinary shares, by the weighted average number of shares of Class B ordinary shares outstanding for the period. |
Income Taxes | Income Taxes FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. |
RESTATEMENT OF PREVIOUSLY ISS_2
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables) | 5 Months Ended |
Dec. 31, 2020 | |
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS | |
Schedule of impact of the restatement on the audited consolidated balance sheet, statements of operations and statements ofcash flows for the Affected periods | As of December 31, 2020 As Previously Restatement Reported Adjustment As Restated Balance Sheet Total assets $ 526,336,354 $ — $ 526,336,354 Liabilities and shareholders’ equity Total current liabilities $ 214,037 $ — $ 214,037 Deferred underwriting commissions 12,950,000 — 12,950,000 Derivative warrant liabilities — 45,156,670 45,156,670 Total liabilities 13,164,037 45,156,670 58,320,707 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders’ equity 508,172,310 (45,156,670) 463,015,640 Preference shares - $0.0001 par value — — — Class A ordinary shares - $0.0001 par value 168 452 620 Class B ordinary shares - $0.0001 par value 1,313 — 1,313 Additional paid-in-capital 5,245,274 10,336,401 15,581,675 Accumulated deficit (246,748) (10,336,853) (10,583,601) Total shareholders’ equity 5,000,007 — 5,000,007 Total liabilities and shareholders’ equity $ 526,336,354 $ — $ 526,336,354 Period From July 22, 2020 (Inception) Through December 31, 2020 As Previously Restatement Reported Adjustment As Restated Statement of Operations Loss from operations $ (249,892) $ — $ (249,892) Other (expense) income: Change in fair value of derivative warrant liabilities — (9,269,010) (9,269,010) Financing cost -derivative warrant liabilities — (1,067,843) (1,067,843) Interest income from investments held in Trust Account 3,144 — 3,144 Total other (expense) income 3,144 (10,336,853) (10,333,709) Net loss $ (246,748) $ (10,336,853) $ (10,583,601) Basic and Diluted weighted-average Class A ordinary shares outstanding 51,232,394 51,232,394 Basic and Diluted net loss per Class A share $ 0.00 $ 0.00 Basic and Diluted weighted-average Class B ordinary shares outstanding 12,648,810 12,648,810 Basic and Diluted net loss per Class B share $ (0.02) $ (0.82) $ (0.84) Period From July 22, 2020 (Inception) Through December 31, 2020 As Previously Restatement Reported Adjustment As Restated Statement of Cash Flows Net cash used in operating activities (1,004,123) — (1,004,123) Net cash used in investing activities (525,000,000) — (525,000,000) Net cash provided by financing activities 526,827,315 — 526,827,315 Net change in cash $ 823,192 $ — $ 823,192 In addition, the impact to the balance sheet dated October 22, 2020, filed on Form 8-K on October 28, 2020 is presented below. As of October 22, 2020 As Previously Restatement Reported Adjustment As Restated Balance Sheet Total assets $ 502,377,315 $ — $ 502,377,315 Liabilities and shareholders’ equity Total current liabilities $ 1,036,746 $ — $ 1,036,746 Deferred underwriting commissions 12,075,000 — 12,075,000 Derivative warrant liabilities — 34,126,000 34,126,000 Total liabilities 13,111,746 34,126,000 47,237,746 Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders’ equity 484,265,560 (34,126,000) 450,139,560 Preference shares - $0.0001 par value — — — Class A ordinary shares - $0.0001 par value 157 342 499 Class B ordinary shares - $0.0001 par value 1,380 — 1,380 Additional paid-in-capital 5,026,968 1,067,501 6,094,469 Accumulated deficit (28,496) (1,067,843) (1,096,339) Total shareholders’ equity 5,000,009 — 5,000,009 Total liabilities and shareholders’ equity $ 502,377,315 $ — $ 502,377,315 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 5 Months Ended |
Dec. 31, 2020 | |
FAIR VALUE MEASUREMENTS | |
Schedule of Company's financial asset measured at fair value on recurring basis | Quoted Significant Significant Prices Other Other in Active Observable Unobservable Markets Inputs Inputs Description (Level 1) (Level 2) (Level 3) Assets Investments held in Trust Account $ 525,003,145 $ — $ — Liabilities Derivative warrant liabilities -Public Warrants $ 33,250,000 $ — $ — Derivative warrant liabilities -Private Warrants $ — $ — $ 11,906,670 |
Schedule of quantitative information regarding Level 3 fair value measurements | As of October 22, 2020 As of December 31, 2020 Volatility 24.0 % 25.8 % Share price $ 9.55 10.33 Risk-free rate 0.68 % 0.36 % Dividend yield 0.0 % 0.0 % |
Schedule of change in the fair value of the derivative warrant liabilities | Warrant liabilities at July 22, 2020 (inception) $ — Issuance of Public and Private Warrants 35,887,660 Change in fair value of warrant liabilities 9,269,010 Warrant liabilities at December 31, 2020 $ 45,156,670 |
DESCRIPTION OF ORGANIZATION, _2
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND BASIS OF PRESENTATION - Additional Information (Details) | Dec. 03, 2020shares | Nov. 27, 2020USD ($)$ / sharesshares | Oct. 22, 2020USD ($)$ / sharesshares | Aug. 07, 2020USD ($)shares | Dec. 31, 2020USS ($)shares | Dec. 31, 2020USD ($)shares | Dec. 31, 2020USD ($)$ / sharesshares | Nov. 26, 2020USD ($) |
Subsidiary, Sale of Stock [Line Items] | ||||||||
Share price per share | $ / shares | $ 10 | |||||||
Offering costs | $ 7,411,300 | |||||||
Deferred underwriting commissions | $ 12,075,000 | $ 12,950,000 | $ 12,950,000 | |||||
Gross proceeds | $ 500,000 | $ 8,900,000 | ||||||
Cash underwriting fees | 7,400,000 | |||||||
Cash held outside the Trust Account | 823,000 | |||||||
Investment of Cash into Trust Account | $ 525,000,000 | |||||||
Threshold minimum aggregate fair market value as a percentage of the assets held in the Trust Account | 80.00% | 80.00% | ||||||
Threshold percentage of outstanding voting securities of the target to be acquired by post-transaction company to complete business combination | 50.00% | 50.00% | ||||||
Minimum net tangible assets upon consummation of the Business Combination | 5,000,001 | |||||||
Threshold percentage of Public Shares subject to redemption without the Company's prior written consent | 15.00% | 15.00% | ||||||
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent) | 100.00% | 100.00% | ||||||
Threshold business days for redemption of public shares | 10 days | 10 days | ||||||
Maximum net interest to pay dissolution expenses | $ 100,000 | $ 100,000 | ||||||
Working capital | 1,100,000 | |||||||
Aggregate purchase price | 25,000 | |||||||
Loans from working capital | $ 0 | |||||||
Sponsor | Founder Shares | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Aggregate purchase price | $ 25,000 | |||||||
Related party debt outstanding | $ 161,000 | |||||||
Initial Public Offering | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of units issued | shares | 50,000,000 | |||||||
Share price per share | $ / shares | $ 10 | |||||||
Offering costs | $ 19,600,000 | |||||||
Deferred underwriting commissions | 12,100,000 | |||||||
Gross proceeds | $ 500,000,000 | |||||||
Initial Public Offering | Sponsor | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of units issued | shares | 15,500,000 | |||||||
Over-allotment | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of units issued | shares | 2,500,000 | |||||||
Offering costs | $ 1,400,000 | |||||||
Deferred underwriting commissions | $ 1,400,000 | |||||||
Period granted for underwriters to exercise option | 45 days | |||||||
Ordinary shares, authorized shares | shares | 5,175,000 | 5,175,000 | 5,175,000 | |||||
Unit price | $ / shares | $ 10 | $ 10 | ||||||
Gross proceeds | $ 25,000,000 | |||||||
Cash underwriting fees | 900,000 | |||||||
Private Placement | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Gross proceeds | $ 8,900,000 | |||||||
Number of warrants issued | shares | 5,933,333 | |||||||
Exercise price of warrants | $ / shares | $ 1.50 | |||||||
Private Placement | Sponsor | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Gross proceeds | $ 500,000 | |||||||
Number of warrants issued | shares | 333,334 | 5,933,333 | ||||||
Exercise price of warrants | $ / shares | $ 11.50 | |||||||
Initial Public Offering and Private Placement | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Share price per share | $ / shares | $ 10 | |||||||
Maturity period of governments securities | 185 days | |||||||
Aggregate proceeds held in the Trust Account | $ 525,000,000 | |||||||
Class B ordinary shares | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Ordinary shares, authorized shares | shares | 40,000,000 | 40,000,000 | ||||||
Number of shares subject to forfeiture (in shares) | shares | 1,293,750 | 0 | 0 | |||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||||||
Class B ordinary shares | Founder Shares | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||||||
Class B ordinary shares | Sponsor | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of shares surrendered | shares | 668,750 | |||||||
Aggregate purchase price | $ 25,000 | |||||||
Class B ordinary shares | Sponsor | Founder Shares | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of shares subject to forfeiture (in shares) | shares | 1,293,750 | 1,875,000 | 1,875,000 | 1,875,000 | ||||
Par value of shares subject to forfeiture | $ / shares | 0.0001 | |||||||
Number of shares surrendered | shares | 581,250 | |||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | 20.00% | ||||||
Class B ordinary shares | Over-allotment | ||||||||
Subsidiary, Sale of Stock [Line Items] | ||||||||
Number of shares surrendered | shares | 668,750 |
RESTATEMENT OF PREVIOUSLY ISS_3
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Impact of the Restatement - Balance Sheet (Details) - USD ($) | Dec. 31, 2020 | Nov. 26, 2020 | Oct. 22, 2020 | Jul. 21, 2020 |
Assets | ||||
Total Assets | $ 526,336,354 | $ 502,377,315 | ||
Current liabilities: | ||||
Total current liabilities | 214,037 | 1,036,746 | ||
Deferred underwriting commissions | 12,950,000 | $ 12,950,000 | 12,075,000 | |
Derivative warrant liabilities | 45,156,670 | 34,126,000 | ||
Total liabilities | 58,320,707 | 47,237,746 | ||
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders' equity | 463,015,640 | 450,139,560 | ||
Shareholders' Equity: | ||||
Preference shares - $0.0001 par value | ||||
Additional paid-in capital | 15,581,675 | 6,094,469 | ||
Accumulated deficit | (10,583,601) | (1,096,339) | ||
Total shareholders' equity | 5,000,007 | 5,000,009 | $ 0 | |
Total Liabilities and Shareholders' Equity | 526,336,354 | 502,377,315 | ||
Class A ordinary shares | ||||
Shareholders' Equity: | ||||
Ordinary shares | 620 | 499 | ||
Class B ordinary shares | ||||
Shareholders' Equity: | ||||
Ordinary shares | 1,313 | 1,380 | ||
As Previously Reported | ||||
Assets | ||||
Total Assets | 526,336,354 | 502,377,315 | ||
Current liabilities: | ||||
Total current liabilities | 214,037 | 1,036,746 | ||
Deferred underwriting commissions | 12,950,000 | 12,075,000 | ||
Total liabilities | 13,164,037 | 13,111,746 | ||
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders' equity | 508,172,310 | 484,265,560 | ||
Shareholders' Equity: | ||||
Additional paid-in capital | 5,245,274 | 5,026,968 | ||
Accumulated deficit | (246,748) | (28,496) | ||
Total shareholders' equity | 5,000,007 | 5,000,009 | ||
Total Liabilities and Shareholders' Equity | 526,336,354 | 502,377,315 | ||
As Previously Reported | Class A ordinary shares | ||||
Shareholders' Equity: | ||||
Ordinary shares | 168 | 157 | ||
As Previously Reported | Class B ordinary shares | ||||
Shareholders' Equity: | ||||
Ordinary shares | 1,313 | 1,380 | ||
Restetament Adjustments | ||||
Current liabilities: | ||||
Derivative warrant liabilities | 45,156,670 | 34,126,000 | ||
Total liabilities | 45,156,670 | 34,126,000 | ||
Class A ordinary shares, $0.0001 par value; shares subject to possible redemption shareholders' equity | (45,156,670) | (34,126,000) | ||
Shareholders' Equity: | ||||
Additional paid-in capital | 10,336,401 | 1,067,501 | ||
Accumulated deficit | (10,336,853) | (1,067,843) | ||
Restetament Adjustments | Class A ordinary shares | ||||
Shareholders' Equity: | ||||
Ordinary shares | $ 452 | $ 342 |
RESTATEMENT OF PREVIOUSLY ISS_4
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Impact of the Restatement - Balance Sheet (Parenthetical) (Details) - $ / shares | Dec. 31, 2020 | Oct. 22, 2020 |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Preference shares, par value | $ 0.0001 | $ 0.0001 |
Class A ordinary shares | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Ordinary shares, par value | 0.0001 | 0.0001 |
Class B ordinary shares | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Ordinary shares, par value | $ 0.0001 | $ 0.0001 |
RESTATEMENT OF PREVIOUSLY ISS_5
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Impact of the Restatement - Statement of Operations (Details) | 5 Months Ended |
Dec. 31, 2020USD ($)$ / sharesshares | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Loss from operations | $ (249,892) |
Change in fair value of derivative liabilities | (9,269,010) |
Financing Costs | (1,067,843) |
Interest income from investments held in Trust Account | 3,144 |
Total other (expense) income | (10,333,709) |
Net loss | (10,583,601) |
As Previously Reported | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Loss from operations | (249,892) |
Interest income from investments held in Trust Account | 3,144 |
Total other (expense) income | 3,144 |
Net loss | (246,748) |
Restetament Adjustments | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Change in fair value of derivative liabilities | (9,269,010) |
Financing Costs | (1,067,843) |
Total other (expense) income | (10,336,853) |
Net loss | $ (10,336,853) |
Class A ordinary shares | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Basic and diluted weighted average shares outstanding | shares | 51,232,394 |
Basic and diluted net income per share | $ / shares | $ 0 |
Class A ordinary shares | As Previously Reported | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Basic and diluted weighted average shares outstanding | shares | 51,232,394 |
Basic and diluted net income per share | $ / shares | $ 0 |
Class B ordinary shares | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Basic and diluted weighted average shares outstanding | shares | 12,648,810 |
Basic and diluted net income per share | $ / shares | $ (0.84) |
Class B ordinary shares | As Previously Reported | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Basic and diluted weighted average shares outstanding | shares | 12,648,810 |
Basic and diluted net income per share | $ / shares | $ (0.02) |
Class B ordinary shares | Restetament Adjustments | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Basic and diluted net income per share | $ / shares | $ (0.82) |
RESTATEMENT OF PREVIOUSLY ISS_6
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS - Impact of the Restatement - Statement of Cash Flows (Details) | 5 Months Ended |
Dec. 31, 2020USD ($) | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Net cash used in operating activities | $ (1,004,123) |
Net cash used in investing activities | (525,000,000) |
Net cash provided by financing activities | 526,827,315 |
Net increase in cash | 823,192 |
As Previously Reported | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | |
Net cash used in operating activities | (1,004,123) |
Net cash used in investing activities | (525,000,000) |
Net cash provided by financing activities | 526,827,315 |
Net increase in cash | $ 823,192 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Class A Ordinary Shares subject to possible redemption (Details) | Dec. 31, 2020USD ($)shares |
Cash Equivalents | $ | $ 0 |
Class A ordinary shares | |
Temporary Equity, Shares Outstanding | shares | 46,301,564 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Income (Loss) Per Common Share (Details) | 5 Months Ended | |
Dec. 31, 2020USS ($)shares | Dec. 31, 2020USD ($)shares | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Unrecognized tax benefits | $ 0 | |
Accrued interest and penalties | 0 | |
Financing cost - derivative warrant liabilities | 1,067,843 | |
Change in fair value of warrant liabilities | $ 9,269,010 | |
Class A ordinary shares | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Shares excluded since their inclusion would be anti-dilutive | shares | 23,766,667 | 23,766,667 |
Interest income earned on the Trust Account | $ 3,000 | |
Class B ordinary shares | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Interest income earned on the Trust Account | 10,600,000 | |
Private Placement Warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Number Of Warrants Shares Outstanding | $ 6,266,667 | |
Public warrants Member | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Number Of Warrants Shares Outstanding | $ 17,500,000 | |
Initial Public Offering | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Financing cost - derivative warrant liabilities | 1,100,000 | |
Change in fair value of warrant liabilities | $ 19,900,000 |
INITIAL PUBLIC OFFERING (Detail
INITIAL PUBLIC OFFERING (Details) - USD ($) | Nov. 27, 2020 | Oct. 22, 2020 | Dec. 31, 2020 | Nov. 26, 2020 |
Subsidiary, Sale of Stock [Line Items] | ||||
Price per share | $ 10 | |||
Proceeds received from initial public offering, gross | $ 525,000,000 | |||
Offering costs | 7,411,300 | |||
Deferred underwriting commissions | $ 12,075,000 | $ 12,950,000 | $ 12,950,000 | |
Number of shares issuable per warrant | 1 | |||
Exercise price of warrants | $ 11.50 | |||
Gross proceeds | $ 500,000 | $ 8,900,000 | ||
Cash underwriting fees | $ 7,400,000 | |||
Initial Public Offering | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Number of units issued | 50,000,000 | |||
Price per share | $ 10 | |||
Proceeds received from initial public offering, gross | $ 500,000,000 | |||
Offering costs | 19,600,000 | |||
Deferred underwriting commissions | 12,100,000 | |||
Exercise price of warrants | $ 11.50 | |||
Gross proceeds | $ 500,000,000 | |||
Initial Public Offering | Sponsor | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Number of units issued | 15,500,000 | |||
Over-allotment | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Number of units issued | 2,500,000 | |||
Offering costs | $ 1,400,000 | |||
Deferred underwriting commissions | $ 1,400,000 | |||
Period granted for underwriters to exercise option | 45 days | |||
Ordinary shares, authorized shares | 5,175,000 | 5,175,000 | ||
Unit price | $ 10 | $ 10 | ||
Gross proceeds | $ 25,000,000 | |||
Cash underwriting fees | $ 900,000 |
PRIVATE PLACEMENT (Details)
PRIVATE PLACEMENT (Details) - USD ($) $ / shares in Units, $ in Millions | Nov. 27, 2020 | Oct. 22, 2020 | Dec. 31, 2020 |
Subsidiary, Sale of Stock [Line Items] | |||
Number of shares per warrant | 1 | ||
Exercise price of warrant | $ 11.50 | ||
Gross proceeds | $ 0.5 | $ 8.9 | |
Private Placement | |||
Subsidiary, Sale of Stock [Line Items] | |||
Number of warrants issued | 5,933,333 | ||
Price of warrants | $ 1.50 | ||
Gross proceeds | $ 8.9 | ||
Private Placement | Class A ordinary shares | |||
Subsidiary, Sale of Stock [Line Items] | |||
Number of shares per warrant | 1 | ||
Exercise price of warrant | $ 11.50 | ||
Sponsor | Private Placement | |||
Subsidiary, Sale of Stock [Line Items] | |||
Number of warrants issued | 333,334 | 5,933,333 | |
Price of warrants | $ 11.50 | ||
Gross proceeds | $ 0.5 | ||
Sponsor | Private Placement | Class A ordinary shares | |||
Subsidiary, Sale of Stock [Line Items] | |||
Number of shares per warrant | 1 | ||
Exercise price of warrant | $ 11.50 |
RELATED PARTY TRANSACTIONS - Fo
RELATED PARTY TRANSACTIONS - Founder Shares (Details) | Dec. 03, 2020USD ($)shares | Oct. 22, 2020USD ($)shares | Aug. 07, 2020USD ($)shares | Dec. 31, 2020USD ($)$ / sharesitemshares |
Related Party Transaction [Line Items] | ||||
Aggregate purchase price | $ | $ 25,000 | |||
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences | 150 days | |||
Sponsor | Founder Shares | ||||
Related Party Transaction [Line Items] | ||||
Aggregate purchase price | $ | $ 25,000 | |||
Class B ordinary shares | ||||
Related Party Transaction [Line Items] | ||||
Number of shares subject to forfeiture (in shares) | shares | 1,293,750 | 0 | ||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||
Consideration on shares surrendered | $ | $ 0 | |||
Class B ordinary shares | Over-allotment | ||||
Related Party Transaction [Line Items] | ||||
Number of shares surrendered | shares | 668,750 | |||
Consideration on shares surrendered | $ | $ 0 | $ 0 | ||
Class B ordinary shares | Founder Shares | ||||
Related Party Transaction [Line Items] | ||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||
Class B ordinary shares | Sponsor | ||||
Related Party Transaction [Line Items] | ||||
Aggregate purchase price | $ | $ 25,000 | |||
Number of shares surrendered | shares | 668,750 | |||
Class B ordinary shares | Sponsor | Founder Shares | ||||
Related Party Transaction [Line Items] | ||||
Number of shares issued | shares | 14,375,000 | |||
Number of shares subject to forfeiture (in shares) | shares | 1,293,750 | 1,875,000 | 1,875,000 | |
Shares Subject To Forfeit Par Value | $ / shares | 0.0001 | |||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||
Number of shares surrendered | shares | 581,250 | |||
Consideration on shares surrendered | $ | $ 0 | |||
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares | $ 12 | |||
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item | 20 | |||
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item | 30 |
RELATED PARTY TRANSACTIONS - Re
RELATED PARTY TRANSACTIONS - Related Party Loans and Administrative Support Agreement (Details) - USD ($) | Oct. 22, 2020 | Aug. 07, 2020 | Dec. 31, 2020 |
Related Party Transaction [Line Items] | |||
Proceeds from Related Party Advances | $ 300,000 | ||
Repayment of advances from related party | $ 161,000 | ||
Amount agreed to pay to sponsor under administrative support agreement | $ 10,000 | ||
Related Party Loans | |||
Related Party Transaction [Line Items] | |||
Maximum loans convertible into warrants | $ 1,500,000 | ||
Price of warrants (in dollars per share) | $ 1.50 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Underwriting Agreement (Details) - USD ($) | Nov. 27, 2020 | Oct. 22, 2020 | Oct. 16, 2020 | Dec. 31, 2020 | Nov. 26, 2020 |
Commitments And Contingencies [Line Items] | |||||
Underwriting discount per unit | $ 0.20 | ||||
Deferred fee per unit | $ 0.35 | ||||
Deferred underwriting fee paid | $ 12,075,000 | $ 12,950,000 | $ 12,950,000 | ||
Underwriting discount amount paid | $ 7,400,000 | ||||
Over-allotment | |||||
Commitments And Contingencies [Line Items] | |||||
Underwriters granted day | 45 days | ||||
Common shares, shares authorized (in shares) | 5,175,000 | 5,175,000 | |||
Number of units issued | 2,500,000 | ||||
Unit Price | $ 10 | $ 10 | |||
Deferred underwriting fee paid | $ 1,400,000 | ||||
Underwriting discount amount paid | $ 900,000 | ||||
Initial Public Offering | |||||
Commitments And Contingencies [Line Items] | |||||
Number of units issued | 50,000,000 | ||||
Deferred underwriting fee paid | $ 12,100,000 | ||||
Initial Public Offering | Sponsor | |||||
Commitments And Contingencies [Line Items] | |||||
Number of units issued | 15,500,000 | ||||
Class B ordinary shares | |||||
Commitments And Contingencies [Line Items] | |||||
Common shares, shares authorized (in shares) | 40,000,000 |
DERIVATIVE WARRANT LIABILITIES
DERIVATIVE WARRANT LIABILITIES (Details) - 5 months ended Dec. 31, 2020 | USS ($)item | $ / shares |
Class of Warrant or Right [Line Items] | ||
Exercise price of warrant | $ 11.50 | |
Private Placement Warrants | ||
Class of Warrant or Right [Line Items] | ||
Number Of Warrants Shares Outstanding | $ | $ 6,266,667 | |
Public warrants Member | ||
Class of Warrant or Right [Line Items] | ||
Number Of Warrants Shares Outstanding | $ | 17,500,000 | |
private placements Member | Private Placement Warrants | ||
Class of Warrant or Right [Line Items] | ||
Number Of Warrants Shares Outstanding | $ | $ 6,266,667 | |
Redeemable warrants | ||
Class of Warrant or Right [Line Items] | ||
Public Warrants exercisable term after the completion of a business combination | 30 days | |
Public Warrants exercisable term from the closing of the initial public offering | 12 months | |
Threshold period for filling registration statement after business combination | 15 days | |
Public Warrants expiration term | 5 years | |
Threshold issue price per share | $ 9.20 | |
Percentage of gross proceeds on total equity proceeds | 60.00% | |
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent) | 115.00% | |
Adjustment of redemption price of stock based on market value and newly issued price (as a percent) | 180.00% | |
Threshold period for not to transfer, assign or sell any of their shares or warrants after the completion of the initial business combination | 30 days | |
Redeemable warrants | Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 | ||
Class of Warrant or Right [Line Items] | ||
Stock price trigger for redemption of public warrants (in dollars per share) | 18 | |
Redemption price per public warrant (in dollars per share) | 0.01 | |
Minimum threshold written notice period for redemption of public warrants | 30 days | |
Threshold trading days for redemption of public warrants | item | 20 | |
Threshold consecutive trading days for redemption of public warrants | item | 30 | |
Threshold business days before sending notice of redemption to warrant holders | 90 days | |
Redeemable warrants | Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $10.00 | ||
Class of Warrant or Right [Line Items] | ||
Fair market value per share | 0.361 | |
Stock price trigger for redemption of public warrants (in dollars per share) | 10 | |
Redemption price per public warrant (in dollars per share) | $ 0.10 | |
Minimum threshold written notice period for redemption of public warrants | 30 days | |
Threshold trading days for redemption of public warrants | item | 20 | |
Threshold consecutive trading days for redemption of public warrants | item | 30 | |
Threshold business days before sending notice of redemption to warrant holders | 90 days | |
Threshold trading days determining volume weighted average price | 10 days |
SHAREHOLDERS' EQUITY - Common S
SHAREHOLDERS' EQUITY - Common Stock Shares (Details) | Dec. 03, 2020USD ($)shares | Nov. 27, 2020shares | Oct. 22, 2020USD ($)$ / sharesshares | Aug. 07, 2020USD ($)shares | Dec. 31, 2020USS ($)shares | Dec. 31, 2020Vote | Dec. 31, 2020$ / shares | Dec. 31, 2020shares |
Class A ordinary shares | ||||||||
Class of Stock [Line Items] | ||||||||
Common shares, shares authorized (in shares) | 400,000,000 | |||||||
Ordinary shares, par value | $ / shares | $ 0.0001 | $ 0.0001 | ||||||
Common shares, votes per share | 1 | 1 | ||||||
Ordinary shares, shares issued | 6,198,436 | |||||||
Ordinary shares, shares outstanding | 6,198,436 | |||||||
common stock shares issued including shares subject to redemption | 52,500,000 | |||||||
Common Stock Shares Outstanding Including Shares Subject To Redemption | 52,500,000 | |||||||
Number of shares subject to possible redemption | 46,301,564 | |||||||
Class B ordinary shares | ||||||||
Class of Stock [Line Items] | ||||||||
Common shares, shares authorized (in shares) | 40,000,000 | |||||||
Ordinary shares, par value | $ / shares | $ 0.0001 | $ 0.0001 | ||||||
Ordinary shares, shares issued | 14,375,000 | 13,125,000 | ||||||
Ordinary shares, shares outstanding | 14,375,000 | 13,125,000 | ||||||
common stock shares issued including shares subject to redemption | 1,875,000 | |||||||
Number of shares subject to forfeiture (in shares) | 1,293,750 | 0 | ||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||||||
Consideration on shares surrendered | $ | $ 0 | |||||||
Class B ordinary shares | Founder Shares | ||||||||
Class of Stock [Line Items] | ||||||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||||||
Class B ordinary shares | Sponsor | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares surrendered | 668,750 | |||||||
Class B ordinary shares | Sponsor | Founder Shares | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares subject to forfeiture (in shares) | 1,293,750 | 1,875,000 | 1,875,000 | |||||
Percentage of issued and outstanding shares after the Initial Public Offering collectively held by initial stockholders | 20.00% | |||||||
Number of shares surrendered | 581,250 | |||||||
Consideration on shares surrendered | $ | $ 0 | |||||||
Over-allotment | ||||||||
Class of Stock [Line Items] | ||||||||
Common shares, shares authorized (in shares) | 5,175,000 | 5,175,000 | ||||||
Number of units issued | 2,500,000 | |||||||
Over-allotment | Class B ordinary shares | ||||||||
Class of Stock [Line Items] | ||||||||
Number of shares surrendered | 668,750 | |||||||
Consideration on shares surrendered | $ | $ 0 | $ 0 | ||||||
Maximum shares subject to forfeiture | 1,293,750 |
SHAREHOLDERS' EQUITY - Preferre
SHAREHOLDERS' EQUITY - Preferred Stock Shares (Details) - $ / shares | Dec. 31, 2020 | Oct. 22, 2020 |
SHAREHOLDERS' EQUITY | ||
Preferred shares, shares authorized | 1,000,000 | |
Preference shares, par value | $ 0.0001 | $ 0.0001 |
Preferred shares, shares issued | 0 | |
Preferred shares, shares outstanding | 0 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) - Measured on a recurring basis | Dec. 31, 2020USD ($) |
Quoted Prices in Active Markets (Level 1) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Investments held in Trust Account | $ 525,003,145 |
Quoted Prices in Active Markets (Level 1) | Public warrants Member | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Derivative warrant liabilities | 33,250,000 |
Significant Other Observable Inputs (Level 2) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Investments held in Trust Account | 0 |
Significant Other Observable Inputs (Level 2) | Public warrants Member | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Derivative warrant liabilities | 0 |
Significant Other Observable Inputs (Level 2) | Private Placement Warrants | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Derivative warrant liabilities | 0 |
Significant Other Unobservable Inputs (Level 3) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Investments held in Trust Account | 0 |
Significant Other Unobservable Inputs (Level 3) | Public warrants Member | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Derivative warrant liabilities | 0 |
Significant Other Unobservable Inputs (Level 3) | Private Placement Warrants | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
Derivative warrant liabilities | $ 11,906,670 |
FAIR VALUE MEASUREMENTS - Trans
FAIR VALUE MEASUREMENTS - Transfers between levels (Details) - USD ($) | Oct. 22, 2020 | Dec. 31, 2020 | Dec. 31, 2020 |
Significant Other Unobservable Inputs (Level 3) | |||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Volatility | 24.00% | 25.80% | |
Share price | $ 9.55 | $ 10.33 | $ 10.33 |
Risk-free rate | 0.68% | 0.36% | |
Dividend yield | 0.00% | 0.00% | |
Measured on a recurring basis | |||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |||
Transfer of assets from level 2 to level 1 | $ 9,300,000 | $ 9,300,000 | |
Transfers to / from Level 3 | $ 0 |
FAIR VALUE MEASUREMENTS - Fair
FAIR VALUE MEASUREMENTS - Fair value of derivative warrant liabilities (Details) | 5 Months Ended |
Dec. 31, 2020USD ($) | |
FAIR VALUE MEASUREMENTS | |
Issuance of Public and Private Warrants | $ 35,887,660 |
Change in fair value of warrant liabilities | 9,269,010 |
Warrant liabilities Ending Balance | $ 45,156,670 |